March 5 (Reuters) - AbbVie Inc : * CEO says Pharmacyclics deal will boost earnings by more than 60 cents per share by 2019, ramp earnings thereafter * CEO says expects Pharmacyclics blood cancer drug ...
(Reuters) - An updated experimental form of AbbVie Inc's (ABBV.N) Humira arthritis drug has clear advantages over the original that could help the company confront looming cheaper biosimilar forms of ...
March 5 (Reuters) - AbbVie Inc said on Thursday it fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc and its hot-selling Imbruvica cancer drug, and expects the medicine to ...
Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...
The U.S. Food and Drug Administration (FDA) approved Novartis' (NYSE:NVS) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback